Nivolumab and relatlimab-rmbw (Opdualag)
Optional dilutionFull monograph review pending
U.S. label preparation
Opdualag · Optional dilution
- Preparation
- The IV product may be infused undiluted. If dilution is selected, use 0.9% sodium chloride or 5% dextrose and meet both components' concentration limits in Table 2.
- Administration and handling
- Maximum infusion volume depends on the patient group. Use the labeled filter and 30-minute infusion.
Product and source details
E.R. Squibb & Sons, L.L.C. · BLA761234
Product NDC: 0003-7125
SPL effective 2026-06-08 | SPL version 3. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.